We are developing ADC therapies for tough-to-treat cancers by unlocking a deeper understanding of drug-resistant tumor biology. 💊 “With cutting-edge research, world-class clinical expertise, and a surge in biotech investment, Barcelona’s next masterpiece could be a first-in-class medicine.” 🚀 Proud to be part of Barcelona’s booming biotech scene… Read More
At ONA Therapeutics we are priviledged to collaborate with top-tier Spanish hospitals to bring our first-in-class ADCs to cancer patients. 🔝 Valerie Vanhooren, CEO and co-founder of ONA Therapeutics is featured in the latest… Read More
Aleix Prat, an internationally recognized leader in drug and biomarker development appointed Chair of the Advisory Board Jutta Amersdorffer appointed as Chief Medical Officer and Stéphane Durant des Aulnois appointed as Chief Financial Officer Accelerating development of first-in-class ADCs in multiple large solid tumor types designed against novel targets with… Read More
Beijing, China and Barcelona, Spain, December 18th, 2023 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, HKEX: 02315), a global biotech company focusing on the discovery and development of novel antibody therapeutics, today announces an antibody evaluation, option and license agreement with Ona Therapeutics (“Ona”), a Spanish biotech company specialized in… Read More
Barcelona, Spain, 23 May 2023: ONA Therapeutics (“ONA”), which is specialized in unravelling novel biology to design biopharmaceuticals attacking advanced cancer, is pleased to announce the appointment of Dr. Pamela Klein as independent member to its board of directors. Dr. Pamela Klein is a medical oncologist and seasoned… Read More
Barcelona, Spain, 2 December 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development of therapeutic biologics targeting lipid metabolism to treat advanced cancer, today announces the appointment of Dr Michel Detheux as Independent Chair to its Board of Directors. Dr Michel Detheux is a veteran biotech executive… Read More
CataloniaBio & HealthTech has recognised ONA Therapeutics with the Biosuccess award 2021 for its consolidation, investment attraction and growth as a spin-off. The event took place during the UnConference, the annual day of debate on the future of healthcare solutions promoted by CataloniaBio & HealthTech. ONA Therapeutics S.L. is a… Read More
Industry veteran in oncology antibody discovery & development Dr Haijun Sun appointed Chief Scientific Officer Expansion of the Scientific Advisory Board with appointments of leading experts in preclinical, translational and clinical drug development Barcelona, Spain, 21 October 2021: ONA Therapeutics (“ONA”), which is focused on the discovery and development… Read More
Barcelona, Spain, March 5th, 2021: Ona Therapeutics, a company focused on the discovery and development of therapeutic biologics to treat metastatic cancer, announces today that it has appointed Dr. Mark Throsby as independent board member of its Board of Directors. Dr. Throsby is a proven senior executive with more than… Read More